五盐酸奥米加南对引起导管相关感染的当代真菌病原体的抗菌活性。
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
作者信息
Fritsche Thomas R, Rhomberg Paul R, Sader Helio S, Jones Ronald N
机构信息
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
出版信息
Antimicrob Agents Chemother. 2008 Mar;52(3):1187-9. doi: 10.1128/AAC.01475-07. Epub 2008 Jan 7.
Abstract
Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at <or=256 microg/ml and molds (including 10 Aspergillus isolates) at <or=1,024 microg/ml. All fungi were inhibited by omiganan at concentrations well below the 1% (10,000 microg/ml) clinical formulation, including species with reduced susceptibility to azoles and echinocandins.
摘要
奥米加南是一种正在开发用作局部凝胶以预防导管相关感染的杀菌和杀真菌阳离子肽，它能抑制常见的真菌病原体，包括念珠菌属（106株分离株），抑菌浓度≤256微克/毫升，对霉菌（包括10株曲霉分离株）的抑菌浓度≤1024微克/毫升。所有真菌在远低于1%（10000微克/毫升）临床制剂浓度时就被奥米加南抑制，包括对唑类和棘白菌素敏感性降低的菌种。
相似文献
1
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
Antimicrob Agents Chemother. 2008 Mar;52(3):1187-9. doi: 10.1128/AAC.01475-07. Epub 2008 Jan 7.
2
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.
J Antimicrob Chemother. 2008 May;61(5):1092-8. doi: 10.1093/jac/dkn074. Epub 2008 Feb 29.
3
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Antimicrob Agents Chemother. 2005 Feb;49(2):512-7. doi: 10.1128/AAC.49.2.512-517.2005.
4
Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.
Antimicrob Agents Chemother. 2004 Aug;48(8):3112-8. doi: 10.1128/AAC.48.8.3112-3118.2004.
5
Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models.
Int J Antimicrob Agents. 2009 Nov;34(5):457-61. doi: 10.1016/j.ijantimicag.2009.05.003. Epub 2009 Jun 12.
6
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Diagn Microbiol Infect Dis. 2008 Apr;60(4):399-403. doi: 10.1016/j.diagmicrobio.2007.11.004. Epub 2008 Feb 21.
7
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).
Diagn Microbiol Infect Dis. 2010 Nov;68(3):278-83. doi: 10.1016/j.diagmicrobio.2010.06.015. Epub 2010 Sep 16.
8
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
J Clin Microbiol. 2008 Mar;46(3):842-9. doi: 10.1128/JCM.02122-07. Epub 2008 Jan 16.
9
In vitro susceptibility of Candida species isolated from blood culture to some antifungal agents.
Jpn J Infect Dis. 2005 Feb;58(1):44-6.
10
Anidulafungin: when and how? The clinician's view.
Mycoses. 2012 Jan;55(1):36-44. doi: 10.1111/j.1439-0507.2011.02052.x. Epub 2011 Jun 13.
引用本文的文献
1
Hydrolysis of Antimicrobial Peptides by Extracellular Peptidases in Wastewater.
Environ Sci Technol. 2024 Jan 9;58(1):717-726. doi: 10.1021/acs.est.3c06506. Epub 2023 Dec 16.
2
Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.
Int J Mol Sci. 2023 Sep 20;24(18):14315. doi: 10.3390/ijms241814315.
3
D- and N-Methyl Amino Acids for Modulating the Therapeutic Properties of Antimicrobial Peptides and Lipopeptides.
Antibiotics (Basel). 2023 Apr 27;12(5):821. doi: 10.3390/antibiotics12050821.
4
In Vitro Activity of Novel Lipopeptides against Triazole-Resistant .
J Fungi (Basel). 2022 Aug 18;8(8):872. doi: 10.3390/jof8080872.
5
Anticandidal Activity of Omiganan and Its Retro Analog Alone and in Combination with Fluconazole.
Probiotics Antimicrob Proteins. 2021 Aug;13(4):1173-1182. doi: 10.1007/s12602-021-09757-9. Epub 2021 Mar 2.
6
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.
Front Immunol. 2020 Sep 17;11:2177. doi: 10.3389/fimmu.2020.02177. eCollection 2020.
7
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial.
Clin Transl Sci. 2020 Sep;13(5):994-1003. doi: 10.1111/cts.12792. Epub 2020 May 1.
8
Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells.
Clin Transl Sci. 2020 Sep;13(5):891-895. doi: 10.1111/cts.12789. Epub 2020 Apr 21.
9
Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers.
Clin Transl Sci. 2020 May;13(3):573-579. doi: 10.1111/cts.12741. Epub 2020 Feb 13.
10
The mechanism of action of pepR, a viral-derived peptide, against Staphylococcus aureus biofilms.
J Antimicrob Chemother. 2019 Sep 1;74(9):2617-2625. doi: 10.1093/jac/dkz223.
本文引用的文献
1
Invasive Candida species infection: the importance of adequate empirical antifungal therapy.
J Antimicrob Chemother. 2007 Sep;60(3):459-60. doi: 10.1093/jac/dkm260. Epub 2007 Jul 23.
2
Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation.
Biochim Biophys Acta. 2007 May;1768(5):1277-90. doi: 10.1016/j.bbamem.2007.02.005. Epub 2007 Feb 17.
3
Vascular catheter-associated infections: a microbiological and therapeutic update.
J Chemother. 2006 Jun;18(3):235-49. doi: 10.1179/joc.2006.18.3.235.
4
Reduction in central line-associated bloodstream infections among patients in intensive care units--Pennsylvania, April 2001-March 2005.
MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1013-6.
5
A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs.
Curr Eye Res. 2005 Jul;30(7):505-15. doi: 10.1080/02713680590968637.
6
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.
J Clin Microbiol. 2005 Apr;43(4):1829-35. doi: 10.1128/JCM.43.4.1829-1835.2005.
7
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.
Am J Infect Control. 2004 Dec;32(8):470-85. doi: 10.1016/S0196655304005425.
8
Clinical-epidemiological characteristics and outcome of patients with catheter-related bloodstream infections in Europe (ESGNI-006 Study).
Clin Microbiol Infect. 2004 Sep;10(9):843-5. doi: 10.1111/j.1469-0691.2004.00955.x.
9
A European perspective on intravascular catheter-related infections: report on the microbiology workload, aetiology and antimicrobial susceptibility (ESGNI-005 Study).
Clin Microbiol Infect. 2004 Sep;10(9):838-42. doi: 10.1111/j.1469-0691.2004.00936.x.
10
Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.
Antimicrob Agents Chemother. 2004 Aug;48(8):3112-8. doi: 10.1128/AAC.48.8.3112-3118.2004.
Zotero 插件